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Abstract
Background: Most reported outcome measures in rheumatoid arthritis (RA) trials are composite, whose
components comprise single measures that are combined into one outcome. The aims of this review were to
assess the range of missing data rates in primary composite outcomes and to document the current practice for
handling and reporting missing data in published RA trials compared to the Consolidated Standards of Reporting
Trials (CONSORT) recommendations.
Methods: A systematic search for randomised controlled trials was conducted for RA trials published between 2008
and 2013 in four rheumatology and four high impact general medical journals.
Results: A total of 51 trials with a composite primary outcome were identified, of which 38 (75 %) used the binary
American College of Rheumatology responder index and 13 (25 %) used the Disease Activity Score for 28 joints
(DAS28). Forty-four trials (86 %) reported on an intention-to-treat analysis population, while 7 trials (14 %) analysed
according to a modified intention-to-treat population. Missing data rates for the primary composite outcome
ranged from 2–53 % and were above 30 % in 9 trials, 20–30 % in 11 trials, 10–20 % in 18 trials and below 10 %
in 13 trials. Thirty-eight trials (75 %) used non-responder imputation and 10 (20 %) used last observation carried
forward to impute missing composite outcome data at the primary time point. The rate of dropout was on average
61 % times higher in the placebo group compared to the treatment group in the 34 placebo controlled trials
(relative rate 1.61, 95 % CI: 1.29, 2.02). Thirty-seven trials (73 %) did not report the use of sensitivity analyses to
assess the handling of missing data in the primary analysis as recommended by CONSORT guidelines.
Conclusions: This review highlights an improvement in rheumatology trial practice since the revision of CONSORT
guidelines, in terms of power calculation and participant’s flow diagram. However, there is a need to improve the
handling and reporting of missing composite outcome data and their components in RA trials. In particular,
sensitivity analyses need to be more widely used in RA trials because imputation is widespread and generally
uses single imputation methods, and in this area the missing data rates are commonly differentially higher in
the placebo group.
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Background
Rheumatoid arthritis (RA) is a chronic autoimmune
inflammatory disease of unknown aetiology. It is challen-
ging to diagnose RA because of the variability in the
disease expression [1–3]. In RA, most reported outcome
measures are composites, with the Disease Activity
Score for 28 joints (DAS28), a continuous measure of
current status of disease activity, and the American
College of Rheumatology (ACR) response criteria, a
binary indicator of disease activity change over time,
being the most commonly used. The ACR response
criteria are defined as 20 % (ACR20), 50 % (ACR50) and
70 % (ACR70) improvement in five of the seven measures
[4, 5].
A composite endpoint or outcome comprises several
single endpoints that are combined into a single outcome.
The use of composite endpoints has been discussed
extensively in the trial literature; for example, they are
used as time-to-event endpoints in cardiovascular, cancer,
diabetic and HIV studies [6, 7], where the composite
might involve binary variables which combine mortality
with non-fatal endpoints such as hospitalisation and
cardiac arrest in chronic heart patients [8]. The advantages
of using composite outcomes are statistical efficiency and
increased precision of risk ratios and other parameter
estimates, arising from a larger event rate, and hence a
smaller sample size needed when designing the trial [9].
An article by Senn and Julious criticised the use of com-
posite response measures, as they argued that their use
should be carefully thought through and accompanied by
consideration of their components [10].
Randomised controlled trials (RCTs) are the gold
standard study design for evaluating treatment efficacy.
Trials with measurements made on the same patient
repeated over time nearly always have an outcome where
patients have missing values at the end of follow-up. A
missing value is an observation that was intended to be
collected from a study subject but for a variety of
reasons was not collected [11]. The presence of missing
data in trials leads to a loss of statistical power to detect
effects through a reduction in the size of the analysed
sample, when imputation is not used. In addition, the
remaining analysed sample may no longer be representa-
tive of the recruited sample, which may introduce bias
into the treatment estimates. For example, in two-arm
trials, these losses and biases can occur differentially in
each arm and for reasons connected with changing
disease outcome, thereby increasing the potential for
incorrect/misleading conclusions from these randomised
comparisons if the missing data is inappropriately handled.
A survey of RCTs in all medical fields in four major
medical journals in 1999 found that a quarter of trials
had more than 10 % of responses missing for the primary
outcome [12]. A similar review in 2004 [13] found that
89 % of trials had reported partially missing data, meaning
that there is some but not all data available for the individ-
ual. In addition, the review showed an unexpectedly high
use of overly simple methods for handling missing data
which ignored the partially available data. Furthermore,
79 % of trials did not report a sensitivity analysis as
recommended by the Consolidated Standards of Reporting
Trials (CONSORT) statement [14, 15].
This paper was motivated by the current practice for
handling and reporting missing data in RA trials, which
has typically involved the use of single imputation
methods that have become outdated, e.g. the single
imputation method using last observation carried forward
(LOCF). Moreover, non-responder imputation (NRI) is
another single imputation method, which assigns a subject
with a missing binary or categorical outcome as if they are
a non-responder. NRI assumes that missing values are
treatment failures, and this assumption is unquestioned
unless a sensitivity analysis is additionally undertaken in
order to explore the impact on the results. The aims of this
review were to assess the range of missing data rates in
primary composite outcomes and to document the
current practice for handling and reporting missing
data in published RA trials compared to CONSORT
recommendations.
Methods
Data sources and search strategy
Trials were identified by searching PubMed and other
resources (hand searched individual journal websites,
Web of Science, Cochrane Central Register of Controlled
Trials and Google Scholar). The Preferred Reporting Items
for Systematic reviews and Meta-Analyses (PRISMA)
guidelines were followed for reporting the review method-
ology [16]. The search terms are given in Additional file 1:
section A.
Selection of studies
Studies were included in the review if they met the
inclusion criteria: phase 3; double blinded RCT con-
ducted in adults with RA; English language papers
published between January 2008 and December 2013;
published in four rheumatology journals (Annals of the
Rheumatic Diseases, Arthritis & Rheumatism, Arthritis
Research & Therapy and Rheumatology); and four high
impact factor general medical journals (Lancet, New
England Journal of Medicine, Journal of the American
Medical Association and the British Medical Journal);
and a composite outcome measure was reported as the
primary outcome.
Data extraction
Data extracted from the papers included the following:
year of publication, journal, source of funding, primary
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and secondary outcomes, trial design; sample size calcula-
tion and whether this calculation included a dropout rate;
amount of missing information (proportion of missing out-
come data in each treatment group after randomisation);
method of dealing with missing primary outcome data;
analysis population (intention-to-treat (ITT), modified ITT,
per protocol, complete or available cases); statistical method
used to analyse the primary outcome; sensitivity analyses;
participant flow diagram (e.g. number randomised in each
group, number included in the ITT analysis, number
completed and number of withdrawals or lost to follow-up)
and study follow-up time. ITT is an approach used to
analyse trial data, where subjects are analysed in their
original randomised group irrespective of whether they
received the intervention or not.
Statistical analysis
Data manipulation and analyses were carried out in Stata
(version 13.0, StataCorp, College Station, TX). The pro-
portion of missing primary outcomes at the primary
time point was defined as: one minus the number of
patients who completed the trial divided by the number
of patients in ITT analysis. The treatment group that we
presented here represents the combined active treatment
groups in each trial; e.g. if a trial had three arms of
which two arms were active treatment and one a placebo,
then the numbers in the two active treatment groups were
combined. To estimate the differential rate of missing
primary outcome data, the relative rate of missing data
was defined to be the rate of missing primary outcome in
the placebo group relative to that in the treatment group.
Summary statistics were presented to describe the charac-
teristics of the studies included in the review. Chi-square
or Fisher’s exact tests were used to compare between the
categories.
Results
Study selection
The initial database search identified 297 unique studies,
from which 196 were selected for a full text examination.
A further 145 articles were excluded, leaving 51 papers
(see Fig. 1). The majority of exclusions at this stage were
made for studies not being in phase 3 or published in
other journals.
Characteristics of included studies
Of the 51 trials published between 2008–2013, 23
(45 %), 11 (22 %) and 17 (33 %) were published in the
periods 2008–2009, 2010–2011 and 2012–2013, respect-
ively (see Table 1). Fifty of the 51 trials were of parallel
design (98 %), and of these, 26 (52 %) were two-arm
treatment comparisons, 14 (28 %) three-arm compari-
sons and the remaining 10 (20 %) had more than three
arms.
The binary ACR20 responder index was the most
frequently reported primary composite outcome in 35
trials (69 %), followed by 12 trials (24 %) reporting
DAS28-ESR as the primary outcome, one trial reporting
DAS28-CRP, and three (6 %) reporting the ACR50
responder index. The DAS28 measures are continuous
composites, and the ACR indices are binary composites.
The median trial duration was 24 weeks (interquartile
range IQR: 14–26 weeks). The mean age and disease
duration of the participants in the trials at baseline
ranged from 46.4 to 60.0 years, and 0.2 to 16.9 years,
respectively.
CONSORT flow diagram
A participant flow diagram was reported in 43 trials
(84 %). There was a rise in the use of the recommended
flow diagram from 74 % in 2008–2009 (pre CONSORT,
revised in 2010) to 93 % in 2011–2013 (post CONSORT).
All nine of the trials published in the general medical
journals reported a flow diagram. For those published in
the specialist rheumatology journals, eight trials did not
report a flow diagram.
Sample size calculation
Forty-three trials (84 %) reported sample size calculations.
Of these, 9 (21 %) trials included an allowance for dropout
in their power calculation. This dropout rate ranged from
5–25 %, and 4 out of 9 trials (44 %) underestimated the
dropout rate (Fig. 2). The proportion of trials that
reported a sample size calculation was similar in trials
published pre and post CONSORT (87 % versus 82 %,
p = 0.715). A similarly high proportion, 37 (73 % of) trials,
reported both a sample size calculation and a participant
flow diagram.
Fig. 1 PRISMA flow diagram for study selection
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The reporting of a sample size calculation and partici-
pant flow diagram shows a direction of improvement with
the introduction of the CONSORT statement (Table 2),
although these improvements were not significant at the
5 % level. In the pre CONSORT revision period, the
number of trials reporting both a sample size calculation
and a participant flow diagram were 16 of 23 trials (70 %),
and in the post CONSORT period the proportion was
slightly higher, 21 of 28 (75 %).
Intention-to-treat analysis
In most trials, it was stated that the primary analyses
were based on the ITT population. Forty-four (86 %) of
the trials reported that ITT analyses were used, while the
remaining 7 (14 %) of the trials analysed the primary
outcome data according to a modified ITT population,
which was defined as all randomised patients who had
taken at least one dose of study medication and had a
baseline and at least one other visit; see Additional file
1: Table S1.
Extent of missingness in the primary composite outcomes
(reporting of missing data)
Missing values were present in primary composite out-
comes for all of the 51 trials. The median missing primary
composite outcome rate was 17 % (IQR 10–25 %) with a
wide range from 2.1–52.7 %. Typically 17 % of the primary
composite outcome data in ITT analyses were imputed
data, and this was considerably higher for some trials. The
rate of imputed missing primary outcome was >30 % in 9
trials (18 %), >20–30 % in 11 trials (22 %), 10–20 % in 18
trials (35 %), and <10 % in 13 trials (25 %).
Table 1 Characteristics of the trials included in the review
Characteristic Number of trials
(N = 51)
Publication year
2008 12 (24 %)
2009 11 (22 %)
2010 7 (14 %)
2011 4 (9 %)
2012 8 (16 %)
2013 9 (18 %)
Journals
Rheumatology journals
Annals of the Rheumatic Diseases 19 (37 %)
Arthritis & Rheumatism 17 (33 %)
Rheumatology 5 (10 %)
Arthritis Research & Therapy 1 (2 %)
General medical journals
Lancet 7 (14 %)
New England Journal of Medicine (NEMJ) 2 (4 %)
British Medical Journal (BMJ) 0 (0 %)
Journal of the American Medical Association (JAMA) 0 (0 %)
Funding
Pharmaceuticals 47 (92 %)
Academic/charity 4 (8 %)
Subjects
Randomised subjects per trial, median (IQR) 159 (102–249)
Mean age in years, median (IQR) 52 (50–54)
Mean disease duration in years, median (IQR) 7.6 (2.3–9.1)
Follow-up time in weeks, median (IQR) 24 (14–26)
12–23 weeks 14 (27 %)
24 weeks 24 (47 %)
>24 weeks 13 (26 %)
Fig. 2 Observed and anticipated dropout rates. Each dot represents
one trial; only 9 trials included dropout rate in the sample
size calculations
Table 2 Conformity with missing data-related CONSORT items
by year of trial publication
Year of publication
CONSORT items 2008–2009
n = 23
2010–2013
n = 28
P value All
N = 51
Sample size
statement given
Yes 20 (87 %) 23 (82 %) 0.638 43 (84 %)
Dropout planned fora 4 (20 %) 5 (22 %) 0.965 9 (21 %)
Flow diagram given
Yes 17 (74 %) 26 (93 %) 0.064 43 (84 %)
Sample size and flow
diagram given
16 (70 %) 21 (75 %) 0.689 37 (73 %)
ITT analysis stated 20 (87 %) 24 (86 %) 0.898 44 (86 %)
Used sensitivity analysis
Yes 5 (22 %) 9 (32 %) 0.4261 14 (27 %)
aA percentage of anticipated dropouts were included in the
power calculations
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Imputation details of the primary composite endpoints
(missing data handling)
In the 38 trials with binary outcomes with imputation of
the whole composite, NRI was used in 29 trials (76 %),
and 6 trials (16 %) used LOCF. Moreover, in 3 trials no
imputation method was used, although these trials had
10–13 % of missing data in the primary outcome data.
Similarly, in the 13 trials that reported DAS28 (which is
a continuous composite containing mixed continuous
and binary constituents), both of these single imputation
methods were prominent, with a greater number, 9
(69 %), using the NRI than LOCF, 4 (31 %).
Some trials used both of these imputation methods in
their outcomes. For example, out of the 38 trials which
reported using NRI, 23 (61 %) also used LOCF. One trial
used both LOCF and multiple imputation (MI). MI is a
general statistical method to analyse incomplete data. It
attempts to impute missing information by repeating the
imputation process multiple times, with each imputation
consisting of a value randomly drawn from a distribution
of likely values determined from the observed data [11].
Four trials reported using the LOCF method to impute
the joint count component only [17–20]. A further two
trials reported imputing the components of the ACR
core set using LOCF [21, 22] while reporting the use of
NRI to impute patients missing the whole primary end-
point (ACR20 responder index).
Simple univariate methods were used to analyse primary
composite binary outcomes such as the Cochran–Mantel–
Haenszel test in 24 trials (47 %), a simple descriptive
comparison (i.e. Fisher’s exact or the chi-square test) in 15
trials (29 %) and the binomial comparison in 4 trials (see
Table 3). Repeated data of the outcome measured over
time was only used in one trial, using a mixed model
analysis [23].
Differential rate of missing outcomes between treatment
and placebo groups
Of the 51 trials, 34 (67 %) were placebo controlled.
There were notable differences in the rate of missing
primary composite outcome data between treatment and
placebo groups. In the treatment group the median rate
was 14 %, whereas in the placebo group the rate was
24 %. A formal comparison of treatment and placebo
groups in these 34 trials provided a relative rate of 1.61
(95 % CI: 1.29, 2.02), indicating that the rate of missing
data in primary composite outcomes was on average
61 % higher in relative terms in the placebo group
compared to the treatment group (Fig. 3). For the
remaining 17 trials that were not placebo controlled, the
median rate of dropout was 11 %, which is lower than
that for the placebo controlled trials. Table 4 shows the
relative rate of missing primary composite outcome data
by length of follow-up. The effect of a higher rate of
placebo group dropout was observed to be a little
stronger in trials with 6 months or longer follow-up
(trend test p = 0.296).
Sensitivity analysis for assessing the handling of missing
data
Of the 51 trials, 14 (27 %) reported the use of a sensiti-
vity analysis (see Additional file 1: Table S1 for full
descriptions). Sensitivity analyses were used in 38 % (11/
29) of trials with more than 15 % missing data in the
primary outcome, and used in 14 % (3/22) of trials with
less than 15 % missing data.
Missing data mechanism
There was no discussion of the impact that the handling
of the missing data might have had on the primary
analysis in any of the trials. An initial detail is to report
the so-called missing data mechanisms, which are used to
describe the assumed relationship between the observed
data and the missing data. Amongst the trials in this
review, only four mentioned the missing data mechanism,
Table 3 Test statistics used to analyse the primary outcome
Test statistics Number (%) n = 51
Cochran–Mantel–Haenszel 24 (47 %)
χ2/Fisher’s exact 15 (29 %)
Logistic regression 5 (10 %)
Binomial comparison 4 (8 %)
ANOVA/ANCOVA 2 (4 %)
Mixed model analysis 1 (2 %)
ANOVA analysis of variance, ANCOVA analysis of covariance
Fig. 3 Differential rate of missing data for the primary composite
outcome in placebo controlled trials. The line of equality represents
no difference between groups; each dot represents one trial. There
are more data points above the line, which indicates that trials
generally have a higher rate of dropout in the placebo group than
in the treatment group
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and further details were given for two of these in
supplementary material [23–26].
Discussion
Our results show that the trials in this review had a wide
range of rates of missing values in the primary compos-
ite outcome. The methods that were used to handle and
report missing data were not clearly reported. This was
particularly the case for the components of the compos-
ite. Often, the reporting of these trials did not follow the
recommendations set out in the CONSORT guidelines
[14, 15]. The majority of trials provided a flow diagram
that contained the number of patients used in the
analysis for the overall primary composite outcome.
While the diagram is informative, it does not include all
the information required. For example, subjects might
be still in the trial and have a missing measurement but
contribute to the primary time point. Furthermore, the
way current trials are reported often means that we
know how many subjects are missing any data within
the overall composite, but not for which of the individ-
ual components it is missing.
The level of missing composite outcome data varied
from 2–53 %, and, typically, 17 % of primary composite
data in ITT analyses were imputed. The extent of miss-
ing data in the components of the composite was
unknown. This is crucial information, as the individual
components might have different amounts of missing
data or have some partial available data which could be
used to inform the primary outcome. We found differen-
tial rates of missing data between treatment and placebo
groups in the placebo controlled trials; the rate was on
average 61 % times higher in the placebo group compared
to the treatment group.
Most of the trials (43/51) provided a power calcula-
tion. However only 9 trials included a dropout rate in
their power calculation, and 44 % of these trials underes-
timated the dropout rate that was allowed for. The
remaining 34/43 trials did not allow for any dropout,
and yet the median missing primary outcome was high,
18 % (12–25 %), which clearly reduces the power of the
study, although the use of single imputation could unsat-
isfactorily be argued to overcome the loss of sample size.
Moreover, some trials reported analysis of a modified
ITT population, which further reduces the numbers
from those in an ITT analysis. Although restricting
analysis to the modified ITT is not expected to intro-
duce bias per se, it will most likely reduce the power of
the trial, may introduce bias and could be contrary to
the spirit of the ITT principle [27].
As recently as 2013, methods known to lead to bias
trial results, i.e. LOCF and NRI, continue to be used.
Furthermore, articles that were published in 2013 (n =
10) reported the use of both methods in the primary
analyses. Single imputation methods, as used widely in
this area, are inappropriate for handling missing outcome
data in trials, as they underestimate the true variability in
the data [28]. In addition, if missing data are inadequately
handled in primary analyses, there is the potential for
misleading conclusions due to inadequately capturing the
true variability in the data. However, there are other
imputation methods that are highly recommended by
experts in the field of missing data, i.e. multiple imputa-
tions [11, 29, 30].
Some trials in this review reported using LOCF to
impute missing joint count constituents of composite
outcomes, while using NRI for subjects missing the
whole primary composite outcome. It was surprising
that most of the trials did not discuss the missing data
mechanism. The choice of the method to handle missing
data relates to an assumption of missingness [12] and
needs to be discussed in sufficient detail for transpar-
ency. It is also important to explore the pattern and
mechanism of missingness and to report these. In our
results, 6 trials mentioned the missing data mechanism.
We also identified a low proportion of trials reporting
a sensitivity analysis, i.e. 14 (27 %). A sensitivity analysis,
in addition to the main analysis, is generally recom-
mended in order to assess the robustness of the study
findings to plausible assumptions made about the miss-
ing data [29, 31] and to increase confidence in the validity
and generalisability of the results. Moreover, the subject’s
primary outcome data were imputed typically for 61 %
more subjects in the placebo group than in the active
treatment group, without challenge to the assumptions.
Our results have similarities with other studies that
report missing data in primary outcome measures. A
recent meta-analysis by Hewitt et al. [32] of quality of
life outcome in musculoskeletal conditions found that
attrition rates of these trials ranged from 4–28 %. It also
showed a differential rate of missing data between
treatment and control groups, which varied from 1–14 %
in the treatment group and 3–25 % in the control group,
respectively. Our study also shows similar results to other
reviews that were carried out a decade ago. A study by
Table 4 Rates of missing data in placebo relative to treatment
group in placebo controlled trials (n = 34)
Months of follow-up Relative rate
Mean (95 % CI)
3 months (n = 12) 1.36 (0.80, 2.29)
6 months (n = 16) 1.72 (1.26, 2.35)
12 months (n = 5) 1.78 (1.19, 2.64)
Total (n = 34)a 1.61 (1.29, 2.02)
17 trials were excluded due to not having a placebo group; trend test
p value = 0.296
CI confidence intervals
aThe total number of trials includes one trial with 24 months follow-up
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Baron et al. [33] in rheumatic disease found high percent-
ages of missing data on structural outcomes, and these
trials did not adhere to the principle of ITT analysis. The
review of Wood et al. [13] also found that inappropriate
methods were used to handle missing primary outcome
data and showed a similarly low percentage of trials
reporting sensitivity analyses compared to our results
(21 % versus 27 %).
Our study has some limitations. First, we searched
four rheumatology and four high impact factor general
medical journals, which excludes RA trials that are
published elsewhere or in lower impact factor journals.
Secondly, we excluded 54 articles that were published in
other journals that did not endorse the CONSORT
statement, although the majority of these articles did not
report a composite outcome at the primary time point.
Thirdly, we restricted our search to trials that reported a
composite outcome as the primary endpoint. It is true
that the space limitations in journals for articles are
limited, and therefore some discrepancies may exist
between the actual method used and the methods that
were reported. Finally, these are RA disease-specific
trials and so are not generalisable to other disease areas
where the primary outcomes might not be of composite
nature.
This study adds to the volume of the existing evidence
of reporting and handling of missing outcome data.
However, these findings require further investigation
because our understanding on whether to impute the
whole composite outcome or the individual components
and then calculate the composite is unknown. Further-
more, there are no guidelines on how to handle missing
data in composite outcome data that result from derived
variables. We therefore designed a simulation study that
uses information from these results to answer this crucial
question.
Conclusions
This review highlights improvements in rheumatology
trial practice since the revision of the CONSORT guide-
lines, in terms of reporting the power calculation and
participant’s flow diagram. However, there is a need to
improve the reporting and handling of missing composite
outcome data and their components. In particular, sensi-
tivity analyses need to be more widely used in RA trials
because imputation is widespread and with assumptions
and variability unchallenged, and missing data rates are
differentially higher in placebo groups in this area.
Recommendations to improve the reporting and handling
of missing data in composite outcome data in RA trials
Our recommendations are as follows:
 Include the missing composite and its components
during follow-up in a table format that shows the
missing proportions in each arm at each time point.
 Choose an appropriate method for handling missing
data by considering the range of currently available
methods. These include multiple imputation and
mixed effects models.
 Discuss the potential missing data mechanism and
the observed pattern of missingness to support the
chosen methods.
 As recommended in the CONSORT guidelines,
conduct a sensitivity analysis to show the robustness
of the primary analysis to the assumptions that are
made when handling missing data.
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